Drug resistance of cancer has dogged oncology since the very early days of chemotherapy and still represents a major obstacle in today’s era of molecular targeted therapy and personalized medicine.

We investigate chemical compounds derived from medicinal plants used in traditional medicines worldwide and analyze their molecular and cellular modes of action and their potential for targeted chemotherapy.

Almost 400 of our publications can be found at the PubMed database (with abstracts and partly open access). click here

Selected publications:

  • Kadioglu O, Fu YJ, Wiench B, Zu YG, Efferth T. Synthetic cajanin stilbene acid derivatives inhibit c-MYC in breast cancer cells. Archives of Toxicology 2016 Mar;90(3):575-88 (IF: 6.6)
  • Zhao Q, Bauer R, Efferth T. Shikonin and its derivatives inhibit epidermal growt5h factor signaling and synergistically kill glioblastoma cells in combination with erlotinib. International Journal of Cancer 2015 Sep 15;137(6):1446-56 (IF: 5.5)
  • Saeed M, Kadioglu O, Khalid H, Sugimoto Y, Efferth T. Activity of the dietary flavonoid, apigenin, against multidrug-resistant tumor cells as determined by pharmacogenomics and molecular docking. Journal of Nutritional Biochemistry 2015;26:44-56. (IF: 4.6)
  • Zeino M, Paulsen MS, Zehl M, Urban E, Kopp B, Efferth T. Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids. Biochemical Pharmacology 2015;93:11-24. (IF: 5.1)
  • Hamm R, Chen YR, Seo EJ, Zeino M, Wu CF, Müller R, Yang NS, Efferth T. Induction of cholesterol biosynthesis by archazolid B in T24 bladder cancer cells. Biochemical Pharmacology 2014;91:18-30. (IF: 5.1)
  • Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJG, Marschall M. The antiviral activities of artemisinin and artesunate. Clinical Infectious Diseases 2008;47:804-811 (IF: 9.4)
  • Li PCH, Lam E, Roos WP, Zdienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Research 2008;68:4347-51. (IF: 9.3)
  • Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Furchtbar S, Zintl F, Mattern J, Volm M. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clinical Cancer Research 2008;14:2405-12. (IF: 8.2)
  • Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochemical Biophysical Acta – Reviews on Cancer 2007;1775:237-262 (IF: 7.6)
  • Efferth T, Li P, Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends in Molecular Medicine 2007;13:353-361 (IF: 10.1)
  • Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V, de Longueville F, Zintl F, Remacle J, Efferth T. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clinical Cancer Research 2006;12:4357-63. (IF: 8.2)
  • Efferth T, Kahl S, Paulus K, Adams M, Rauh R, Boechzelt H, Hao X, Kaina B, Bauer R. Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther 2008;7:152-61. (IF: 6.2)
  • Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F, Remacle J, Steinbach D. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2006;5:1986-94. (IF: 6.2)
  • Efferth T, Volm M. Pharmacogenetics and individualized cancer chemotherapy. Pharmacology and Therapeutics 2005;107:155-176 (IF: 7.7)
  • Efferth T. Mechanistical perspectives of 1,2,4-trioxanes for anti-cancer therapy. Drug Resistance Updates 2005;8:85-97 (IF: 8.8)
  • Efferth T, Bachli EB, Schwarzl SM, Goede JS, West C, Smith JC, Beutler E. Glucose-6-phosphate dehydrogenase (G6PD) deficiency-type Zurich: a splice site mutation as an uncommon mechanism producing enzyme deficiency. Blood 2004;104(8):2608. (IF: 9.8)